key: cord-1051980-v5s43i76 authors: Bousquet, Jean; Jutel, Marek; Akdis, Cezmi A; Klimek, Ludger; Pfaar, Oliver; Nadeau, Kari C; Eiwegger, Thomas; Bedbrook, Anna; Ansotegui, Ignacio J; Anto, Josep M; Bachert, Claus; Bateman, Eric D; Bennoor, Kazi S; Berghea, Emilia Camelia; Bergmann, Karl‐Christian; Blain, Hubert; Bonini, Mateo; Bosnic‐Anticevich, Sinthia; Boulet, Louis‐Philippe; Brussino, Luisa; Buhl, Roland; Camargos, Paulo; Canonica, G Walter; Cardona, Victoria; Casale, Thomas; Chinthrajah, Sharon; Akdis, Mübeccel; Chivato, Tomas; Christoff, George; Cruz, Alvaro A; Czarlewski, Wienczyslawa; Del Giacco, Stefano; Du, Hui; El‐Gamal, Yehia; Fokkens, Wytske J; Fonseca, Joao A; Gao, Yadong; Gaga, Mina; Gemicioglu, Bilun; Gotua, Maia; Haahtela, Tari; Halpin, David; Hamelmann, Eckard; Hoffmann‐Sommergruber, Karin; Humbert, Marc; Ilina, Nataliya; Ivancevich, Juan‐Carlos; Joos, Guy; Khaitov, Musa; Kirenga, Bruce; Knol, Edward F; Ko, Fanny W; Koskinen, Seppo; Kowalski, Marek L; Kraxner, Helga; Kudlay, Dmitri; Kuna, Piotr; Kupczyk, Maciej; Kvedariene, Violeta; Abdul Latiff, Amir H; Le, Lan T; Levin, Michael; Larenas‐Linnemann, Desiree; Louis, Renaud; Masjedi, Mohammad R; Melén, Erik; Mihaltan, Florin; Milenkovic, Branislava; Mohammad, Yousser; Morais‐Almeida, Mario; Mullol, Joaquim; Namazova, Leyla; Neffen, Hugo; Nunes, Elisabete; O’Byrne, Paul; O’Hehir, Robyn; O’Mahony, Liam; Ohta, Ken; Okamoto, Yoshitaka; Onorato, Gabrielle L; Panzner, Petr; Papadopoulos, Nikos G; Passalacqua, Gianni; Patella, Vincenzo; Pawankar, Ruby; Pham‐Thi, Nhân; Pigearias, Bernard; Popov, Todor A; Puggioni, Francesca; Regateiro, Frederico S; Rolla, Giovanni; Rottem, Menachem; Samolinski, Boleslaw; Sastre, Joaquin; Schwarze, Jurgen; Sheikh, Aziz; Scichilone, Nicola; Soto‐Quiros, Manuel; Sova, Milan; Nicola, Stefania; Stelmach, Rafael; Suppli‐Ulrik, Charlotte; Taborda‐Barata, Luis; To, Teresa; Tomazic, Peter‐Valentin; Toppila‐Salmi, Sanna; Tsiligianni, Ioanna; Usmani, Omar; Valiulis, Arunas; Ventura, Maria Teresa; Viegi, Giovanni; Vontetsianos, Theodor; Wang, De Yun; Williams, Sian; Wong, Gary WK; Yorgancioglu, Arzu; Zernotti, Mario; Zidarn, Mihaela; Zuberbier, Torsten; Agache, Ioana title: ARIA‐EAACI statement on Asthma and COVID‐19 (June 2, 2020) date: 2020-06-26 journal: Allergy DOI: 10.1111/all.14471 sha: 6a730ea3a7f6cdeb8603958ba5cafdde3d2ad23a doc_id: 1051980 cord_uid: v5s43i76 nan A novel strain of human coronaviruses, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), named by the International Committee on Taxonomy of Viruses (ICTV) 1 , has recently emerged and caused an infectious disease. This disease is referred to as the "coronavirus disease 2019" by the World Health Organization (WHO) 2 . The US Centers for Disease Control and Prevention (CDC) have proposed that "People with moderate to severe asthma may be at higher risk of getting very sick from COVID-19. COVID-19 can affect your respiratory tract (nose, throat, lungs), cause an asthma attack, and possibly lead to pneumonia and acute respiratory disease." (May 24, 2020) . (https://www.cdc.gov/coronavirus/2019-ncov/need-extraprecautions/asthma.html) On the other hand, in the UK, NICE proposes rapid guidelines for severe asthma (https://www.guidelines.co.uk/covid-19-rapid-guideline-severe-asthma/455275.article). An ARIA-EAACI statement has been devised to make recommendations on asthma, and not necessarily on severe asthma, based on a consensus from its members. It is difficult to clearly assess the prevalence of asthma on COVID-19 in many studies since most patients are older adults and probably have multimorbidities. Most studies do not clarify whether asthmatic patients with COVID-19 have isolated asthma or asthma as a multimorbidity, particularly in the context of hypertension, obesity and diabetes. In particular, obesity is a significant risk factor for COVID-19 and its severity 3 , and may be intertwined with asthma. In some studies, showing data mostly on critically ill patients, there does not appear to be an increased prevalence of asthma [4] [5] [6] [7] . In Wuhan, the prevalence of asthma in COVID-19 patients was 0.9%, markedly lower than that of the general adult population of this city 8 This article is protected by copyright. All rights reserved (UK), it was found an increased risk of severe COViD-19 in patients with asthma, including death, in particular related with the recent use of oral corticosteroid 13 . A review with all identified studies up to May 5, 2020 is available 14 . However, low socioeconomic status, obesity, non-white ethnicity, chronic respiratory disease and diabetes had stronger signals. Some anti-asthma medications, such as ciclesonide, might have a beneficial effect on COVID-19 15 . Thus, whether patients with asthma are at a higher or lower risk of acquiring COVID-19 may depend on geography, age, other multimorbidities, different air quality 16 , genetic predispositions, ethnicity, social behaviour, access to health care or other factors. Moreover, the current information is obtained mainly from hospitalization or intensive care unit data. Real-life data in a non-selected population of asthmatics are needed to better understand the links between asthma and SARS-Cov-2 in terms of both incidence and severity. Asthma does not seem to be a risk factor for severe COVID-19 but patients treated with oral corticosteroids may be at higher risk of severe COVID-19 14 . However, a large study is needed to fully appreciate the relationship between COVID-19 and severe asthma. According to the IPCRG (International Primary Care Respiratory Group), patients are still struggling to differentiate their symptoms between asthma flare-ups and COVID-19. They may therefore delay seeking care for asthma or COVID-19. Interestingly, clarity does not appear to have improved as the weeks have passed. People have recurrences or waves of repeated symptoms and it is difficult to understand whether the symptoms are related to an asthma exacerbation or to COVID-19. According to IPCRG, many clinicians tend to prescribe antibiotics to people who they believe are having asthma exacerbations "just to be safe". They focus on the potential infection element of the trigger more than the asthma management itself. It would seem that COVID-19 might exacerbate this behaviour, not improve it. In areas where COVID-19 is prevalent, GPs are still very concerned about oral -and, to a certain degree, inhaled -corticosteroids, possibly because they used remote models of care. They are reluctant to prescribe higher doses of ICS or OCS as they fear they cannot tell the difference between a flare-up and COVID-19. This article is protected by copyright. All rights reserved The extent of expression in the upper and lower airways of the SARS-CoV-2 entry receptors, angiotensin-converting enzyme 2 (ACE2) and TMPRSS2, might impact the clinical severity of COVID-19. ACE-2 was found to be decreased in patients with allergic asthma 17 or in those receiving inhaled corticosteroids 18 . These data suggest that this expression may be a potential contributor, among several other factors, to reduced COVID-19 severity in patients with T2 inflammation 17 , 19 However, ACE-2 expression in asthma patients was increased in African-Americans, in males and in association with diabetes (21). Finally, a recent study which analysed the nasal transcriptome from 695 children suggested that the strongest determinants of airway ACE2 and TMPRSS2 expression are T2 inflammation and viral-induced interferon inflammation 20 . However, this study specifically showed that T2 inflammation (via IL-13) impacted differentially on ACE2 and TMPRSS2, with a T2-high phenotype being associated with a highly significant decrease in the former and a significant decrease in the latter receptor. Thus, although SARS-CoV-2-specific analyses and experiments are lacking, the differential effects of T2-inflammation on ACE2 and TMPRSS2 reported in this study warrant further research on whether T2-high and T2-low asthma phenotypes may be associated with differential susceptibility to severe COVID-19. The first author developed seven recommendations that were sent to 105 experts around the world for comment. 69 answers were received within 48 hours and the comments were considered. Where experts suggested modification of the recommendations, a discussion was initiated and recommendations modified until consensus was reached. After these modifications, a total of 9 recommendations were proposed for a second round. In the second round, 145 experts were invited to comment on and approve or reject the recommendations. 78 answers were received within 48 hours and, when an agreement of over 80/100 was reached, the question was included in the statement. The same approach was used for the research questions. Two research needs were dropped. The geographic distribution of the experts is given in Figure 1 . They were from 43 countries. (Table 1) ARIA-EAACI research questions (Table 2 ) This view is pragmatic, cautious and based upon expert opinion. However, it is likely to require modifications as further evidence is gathered. These recommendations are conditional and should be adapted regularly on the basis of evolving clinical evidence. Long-term oral corticosteroids may sometimes be required to treat severe asthma, and it may be dangerous to stop them suddenly (GINA). Oral steroids should continue to be used to treat severe asthma exacerbations. In patients infected by SARS-CoV-2 (symptomatic or asymptomatic), nebulisation (which increases the risk of deposition of virus into the lower airways) should be replaced by spacers of large capacity. In accordance with the NICE in non-SARS-CoV-2 infected patients, we propose https://www.nice.org.uk/guidance/ng166/chapter/3-Treatment#patients-having-biologicaltreatment:  To continue biologics because there is no evidence that biological therapies for asthma suppress immunity  If the patient usually attends a hospital for biological treatments, think about if he/she can be trained to self-administer, or could be treated at a community clinic or at home  To carry out routine monitoring of biological treatment remotely if possible 8 In SARS-CoV-2 infected patients, in accordance with the EAACI we propose to cease the treatment until resolution of the disease is established. Thereafter, the administration of the biological should be re-initiated. This article is protected by copyright. All rights reserved Real-world studies need to be carried out on a large number of unselected patients to assess 1 Impact of COVID-19 on asthma control 2 Impact of COVID-19 respiratory symptoms on severe asthma 3 Impact of severe asthma on COVID-19 occurrence and/or severity of pneumonia 4 Impact of multimorbidities on asthmatic patients for the control of asthma during COVID-19 5 Serologic studies should be performed to assess whether seroconversion and its duration differ in asthmatic and non-asthmatic subjects 6 The phenotype of asthma (allergic, neutrophilic, age….) should be studied 7 In adult patients, studies should clarify whether asthmatic patients with COVID-19 have isolated asthma or asthma in the context of multimorbidity, particularly in the context of high blood pressure, obesity and diabetes mellitus Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region The impact of COPD and smoking history on the severity of Covid-19: A systemic review and meta-analysis Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2. Allergy Eleven Faces of Coronavirus Disease Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the From Containment to Mitigation of COVID-19 in the US Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients Asthma and the COVID-19 pandemic: literature review Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs Exposure to air pollution and COVID-19 mortality in the United States: A nationwide cross-sectional study Association of Respiratory Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2 COVID-19 Related Genes in Sputum Cells in Asthma: Relationship to Demographic Features and Corticosteroids Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium CONFLICT OF INTEREST : IA reports and Associate Editor of Allergy Swiss National Science Foundation, Christine Kühne-Center for Allergy Research and Education, European Commission's Horison's 2020 Framework Programme, Cure, Novartis Research Institutes EB is a member of the Science Committee and Board of the Global Initiative for Asthma (GINA) Merck, personal fees from AstraZeneca, GSK, Merck, Metapharm, Novartis, Takeda, other from AstraZeneca JB reports personal fees from Chiesi RB reports grants to Mainz University and personal fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Roche, as well as personal fees from AstraZeneca VC reports personal fees from ALK, Allergopharma, Allergy Therapeutics, Diater, LETI, Thermofisher, Stallergenes RSC reports grants from NIAID, CoFAR, Aimmune, DBV Technologies, Astellas, Regeneron, an Advisory member for Alladapt, Genentech, Novartis, and receives personal fees from Before Brands System Disorders pending, a patent Mixed Allergen Compositions and Methods for Using the Same pending Microfluidic Device and Diagnostic Methods for Allergy Testing Based on Detection of Basophil Activation pending grants and personal fees from Kyorin Co., Ltd YO reports personal fees from Yamada Bee Farm, outside the submitted work Laboratorios LETI/LETI Pharma, grants from Biomay, Glaxo Smith Kline Circassia, personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA 2 LEN Partner), Indoor Biotechnologies FP reports sanofi, novartis, teva, astrazeneca, glaxosmithkline, menarini, mundipharma, guidotti, malesci, chiesi, valeas, allergy therapeutics, almirall, personal fees from boehringer Ingelheim JS reports other from MEDA, grants and personal fees from SANOFI, personal fees from JSchwarze reports personal fees from MYLAN, outside the submitted work RS reports grants from São Paulo Research Foundation, MSD,grants and personal fees from Novartis, grants, personal fees and non-financial support from AstraZeneca, Chiesi IT reports grants from GSK Hellas, ELPEN, personal fees from Boehringer Ingelheim, Novartis, Astra Zeneca, GSK. TZ reports Organizational affiliations: Commitee member: WHO-Initiative "Allergic Rhinitis and Its Impact on Asthma Head: European Centre for Allergy Research Foundation (ECARF); President: Global Allergy and Asthma European Network (GA 2 LEN); Member: Committee on Allergy Diagnosis and Molecular Allergology AC reports grants and personal fees from GSK, SANOFI, Boehringer-Ingelheim, Astrazeneca, Mantecorp, MYLAN, Novartis, personal fees and non-financial support from CHIESI.SdG reports personal fees from AstraZeneca, Chiesi, Menarini, grants and personal fees from GSK, Novartis. DH reports personal fees from AstraZeneca, Chiesi, GSK, Pfizer, personal fees and non-financial support from Boehringer Ingelheim, Novartis.TE reports other from DBV, Regeneron, grants from Innovation fund Denmark and Co-I or scientific lead in three investigator initiated oral immunotherapy trials supported by the Allergy and Anaphylaxis Program Sickkids and serve as associate editor for Allergy. Advisory board ALK JF reports personal fees from AstraZeneca, GSK, undipharma, grants and personal fees from Novartis.MG reports grants and personal fees from Elpen, Novartis, Menarini, grants from Galapagos, personal fees from BMS, MSD.TH reports personal fees from GSK, Mundipharma, OrionPharma. Nadeau has a patent Inhibition of Allergic Reaction to Peanut Allergen using an IL-33 Inhibitor pending, a patent Special Oral Formula for Decreasing Food Allergy Risk and Treatment for Food Allergy pending, a patent Basophil Activation Based Diagnostic Allergy Test pending, a patent Granulocyte-based methods for detecting and monitoring immune system disorders pending, a patent Methods and Assays for Detecting and Quantifying Pure Subpopulations of White Blood Cells in Immune This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved